Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy.
OBJECTIVE
Since its introduction, capsule endoscopy (CE) has made it possible to visualize the small intestine mucosa directly. However, owing to the limited battery life, only 60-80% of the capsules could reach the cecum and would possibly affect the diagnostic yield. The aim of this study was to determine the effect of oral mosapride on gastrointestinal transit time and the diagnostic yield of CE.


METHODS
Sixty patients were involved in this randomized, prospective and controlled study. The patients were randomly allocated to groups receiving either mosapride citrate or nothing. Patients in the mosapride group (n = 30) received 10 mg mosapride citrate 1 h before CE examination, while patients in the control group (n = 30) received no preparation. The gastrointestinal transit time, the number of CE reaching the cecum, and the diagnostic yield of each group were assessed in a single-blinded fashion.


RESULTS
Gastric emptying time was significantly shorter in the mosapride group than in the control group (13.5 min vs 34 min P = 0.035). Compared with the control group, the complete transit rate was significantly higher in the mosapride group (93.3% vs 66.7% P = 0.021). There was no significant difference between the two groups on the small bowel transit time and diagnostic yield.


CONCLUSIONS
Mosapride citrate accelerates the gastric emptying and completion rate of small bowel examination in patients undergoing CE.
Wei
Wei
W
Department of Gastroenterology, Renji Hospital, Shanghai Institute of Digestive Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ge
Zhi-Zheng
ZZ
Lu
Hong
H
Gao
Yun-Jie
YJ
Hu
Yun-Biao
YB
Xiao
Shu-Dong
SD
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D053704:Capsule Endoscopy; D016009:Chi-Square Distribution; D002648:Child; D005260:Female; D005765:Gastrointestinal Agents; D005767:Gastrointestinal Diseases / Q000175:diagnosis* / Q000503:physiopathology; D005772:Gastrointestinal Transit / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines; D011446:Prospective Studies; D016037:Single-Blind Method; D018709:Statistics, Nonparametric
D001549:Benzamides; D005765:Gastrointestinal Agents; D009025:Morpholines; C062720:mosapride